RVL Logo NO INC.png
RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales
January 09, 2023 06:50 ET | RVL Pharmaceuticals plc
-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for...
RVL Logo NO INC.png
RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
December 01, 2022 08:57 ET | RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief...
RVL Logo NO INC.png
RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
November 10, 2022 16:05 ET | RVL Pharmaceuticals plc
-- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics...
RVL Logo NO INC.png
RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial Update
November 03, 2022 16:05 ET | RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
RVL Logo NO INC.png
RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales
October 18, 2022 06:50 ET | RVL Pharmaceuticals plc
--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product...
RVL Logo NO INC.png
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 16:05 ET | RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief...
RVL Logo NO INC.png
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc
August 30, 2022 06:50 ET | RVL Pharmaceuticals plc
DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc...
RVL Logo NO INC.png
RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update
August 11, 2022 06:50 ET | RVL Pharmaceuticals plc
-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- --...
RVL Logo NO INC.png
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
August 04, 2022 17:06 ET | RVL Pharmaceuticals plc
-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at...
RVL Logo NO INC.png
RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update
August 04, 2022 06:50 ET | RVL Pharmaceuticals plc
BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...